Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.

Fiche publication

Date publication

décembre 2025

Journal

ESMO gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr FEIN Francine , Pr GHIRINGHELLI François , Dr HERVOUET Eric , Mme BOUARD Adeline , Dr VERNEREY Dewi , Dr VIENOT Angélique , Dr FUMET Jean-David , Dr SELMANI Zohair , Mme MEURISSE Aurélia

Tous les auteurs :
El Kaddissi A, Vienot A, Fumet JD, Meurisse A, Nguyen T, Klajer E, Bouard A, Spehner L, Fein F, Stouvenot M, Dochy E, Rebucci-Peixoto M, Almotlak H, Henriquez J, Selmani Z, Vernerey D, Hervouet E, Folletet A, Kim S, Ghiringhelli F, Borg C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42404549

Résumé

Treatment of chemotherapy-resistant metastatic colorectal cancers (mCRCs) is still an unmet medical need. Combining regorafenib, an antiangiogenic multikinase inhibitor with metronomic chemotherapy and aspirin may enhance efficacy to circumvent the tumor microenvironment and offer better clinical outcomes. REPROGRAM-01 was a signal-seeking phase II study assessing the efficacy and safety of multimodal metronomic chemotherapy combined with regorafenib (NCT04534218).